Exelixis(EXEL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 csenner@exelixis.com Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@exelixis.com Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of$379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Diluted EPS of$0.12, Non-GAAP Diluted EPS of $0.17 - - ...